NC
MIRM icon

nVerses Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

nVerses Capital’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447K Buy
+3,822
New +$384K 0.69% 11

Other funds holding MIRM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

nVerses Capital's MIRM Position: Q2 2026 in Review

nVerses Capital opened a new position in Mirum Pharmaceuticals (MIRM) in Q2 2026: 3,822 shares worth $447K. The stake represents 0.69% of the portfolio and ranks #11 among its holdings.

226 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • nVerses Capital held 3,822 shares of Mirum Pharmaceuticals worth $447K as of Q2 2026.
  • Mirum Pharmaceuticals was a new nVerses Capital position in Q2 2026.
  • Mirum Pharmaceuticals made up 0.69% of nVerses Capital's portfolio in Q2 2026, its #11 holding.
  • 226 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.